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ABSTRACT 
β-glucan particles (GP) are polymeric carbohydrates, mainly found as components of cell wall fungi, yeast, bac-
teria and also in cereals such as barley and oat, and have been recently shown to have application in macrophage-
targeted drug delivery. The aim of this study was to prepare and characterize GP containing a large payload of 
Rifabutin (RB), an anti-tuberculosis drug effective against MDR-TB at lower MIC than Rifampicin. GP were 
prepared from yeast cells by acidic and alkaline extraction were either spray dried or lyophilized, prior to RB 
loading and alginate sealing. The FTIR and 13C-NMR spectra of the GP confirmed a β-(1→3) linked glucan struc-
ture, with a triple-helical conformation. The spray dried GP exhibited better characteristics in terms of uniformity, 
size range (2.9 to 6.1 µm) and more than 75 % particles were below 3.5 μm. The RP-HPLC analysis of spray dried 
GP revealed drug entrapment and drug loading up to 81.46 ± 4.9 % and ~40.5 ± 1.9 %, respectively, as compared 
to those dried by lyophilization. Electron microscopy showed nearly spherical and porous nature of GP, and the 
presence of drug ‘nanoprecipitates’ filling the pore spaces. The formulation showed adequate thermal stability for 
pharmaceutical application. The particles were readily phagocytosed by macrophage(s) within 5 min of exposure. 
Drug release occurred in a sustained manner via diffusion, as the release kinetics best fit for drug release was 
obtained using Higuchi’s equation. Thus, the spray dried GP-based-formulation technology holds promise for en-
hanced targeted delivery of anti-TB drug(s) to macrophage within a therapeutic window for the clearance of intra-
cellular bacteria. 
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INTRODUCTION 
Tuberculosis (TB) still causes ~1.5 mil-
lion deaths worldwide, amounting to over 
95 % of the deaths in low and middle-income 
countries (WHO, Tuberculosis fact sheet, Oc-
tober 2014). The ‘Directly Observed Treat-
ment, Short Course’ chemotherapy (DOTS) 
treatment regimen is long and arduous, mak-
ing patient compliance difficult and leading to 
the rapidly expanding problem of drug re-
sistance. Macrophage serve as the primary 
cells where the Mycobacteria invade and ac-
tively replicate within maturation arrested 
phagosomes (Hestvik et al., 2005). The tar-
geted delivery of anti-TB drugs to these cells, 
therefore, forms an effective therapeutic ap-
proach against TB. Recent researches by sev-
eral investigators on drug-loaded particulate 
delivery systems such as microparticles (Sua-
rez et al., 2001; Sen et al., 2003; Verma et al., 
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2013; Goyal et al., 2015), nanoparticles (Za-
hoor et al., 2005), liposomes (Gursoy et al., 
2004) etc. have shown positive results for TB 
therapy. Such particles are rapidly phagocy-
tosed by Mϕ (Hirota et al., 2010), and lead to 
the development of high intracellular drug 
concentrations (Sharma et al., 2001), Mϕ ac-
tivation (Sharma et al., 2007; Yadav et al., 
2009; Sharma et al., 2011) and significant en-
hancement in the anti-microbial efficacy of 
the loaded drugs (Sen et al., 2003; Quenelle et 
al., 1999).  
Particulate delivery systems offer ad-
vantages such as improved bioavailability, 
particularly of hydrophobic drugs; extended 
drug half life; the possibility of controlled re-
lease and low drug wastage. However, the 
development of effective drug delivery 
system(s) presents multiple challenges, such 
as issues of drug solubility, selective 
targeting, in vivo stability and toxicity. Sev-
eral delivery systems have been developed for 
targeting drug molecules specifically to mac-
rophages based on the pattern-recognition re-
ceptors (PRR) on their surface (Etzerodt et al., 
2012; Tiwari et al., 2011; Zhao et al., 2013; 
Zhu et al., 2013). Targeted delivery helps to 
reduce drug dose(s) and dosing frequencies, 
drug toxicity and side effects, and thus hold 
promise for improved patient compliance. 
However, the expression of PRR ligands on 
carrier surface involves intricate procedures.  
β-Glucan particles (GP) extracted from 
the cell walls of baker’s yeast are porous, 1–4 
µm spherical shells composed primarily of β-
1,3/1,6-D-glucan (Soto et al., 2010, 2012). β-
1,3 glucans serve as pathogen associated mo-
lecular patterns (PAMPs), that engage dectin-
1 receptors on Mϕ, leading to their activation 
and the induction of an immune response 
(Herre et al., 2004; Batbayar et al., 2012). The 
hollow cavity within the GP allows adsorp-
tion and encapsulation of payload molecules, 
and thus GP have been used as effective de-
livery vehicle(s) to target Mϕ in the recent 
years (Soto et al., 2010; Yu et al., 2015). β-
Glucan exists in single or triple helical con-
formation in solution, of which the triple hel-
ical configuration glucans have been reported 
as powerful immunomodulators (Falch et al., 
2000).  
One significant aspect of drug targeting is 
to deliver a sufficiently large amount of drug 
to the target cells, so that the resulting intra-
cellular drug concentrations are maintained 
within the therapeutic window (above MIC) 
over a period of time, and ensure complete 
killing of mycobacteria residing in Mϕ. Re-
cently, an anti-TB drug, rifampicin (Rif) had 
been encapsulated within GP, and was found 
effective in reducing M. tb. burden within in-
fected bone marrow Mϕ (Soto et al., 2010). 
These particles contained payloads ranging 
from 10 to 33 % w/w Rif/GP, and displayed 
rapid release of the drug through the polymer 
matrix within the first 24 h. The 10 % w/w 
GP-Rif-Alg formulation contained ~0.2 pg 
Rif/glucan particle, representing only 80 % of 
the MIC of free Rif (0.25 μg/mL). However, 
these particles showed an 80 to 90 % inhibi-
tion of CFU recovered from macrophage ly-
sates after 24 or 72 h of incubation, respec-
tively. Low drug loading and lack of control 
over timed release implies a need for repeated 
administration, inability to address the non-
compliance problem and thus, a risk for de-
velopment of drug resistance. It is thus highly 
desirable to develop GP formulations with a 
larger proportion of the incorporated drug 
payload, for their use as efficient macro-
phage-targeting drug delivery systems against 
TB. Moreover, while the standard TB therapy 
recommends the use of rifamycins as part of 
the DOTS short course therapy (Boogaard et 
al., 2009), the increasing resistance to Rif em-
phasizes the need for new effective drug(s) 
against TB. The anti-TB drug Rifabutin (RB) 
was thus selected for incorporation into GP 
owing to its higher efficacy (lower MIC 
range), relevance in MDR-TB treatment (Jo et 
al., 2013) and longer half-life than Rif (Dick-
inson et al., 1987; Blaschke and Skinner, 
1996).  
In continuation with the ongoing research 
on polymeric formulations against TB, the 
prime objective of the present investigation 
was to prepare biocompatible GP-based for-
mulations containing a high-payload of the 
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anti-TB drug, RB for Mϕ targeted drug deliv-
ery. Yeast derived GP were loaded with RB 
and characterized for their size, morphology, 
drug loading, drug release kinetics and in 
vitro uptake by Mϕ. In addition, analytical 
techniques were used to evaluate the chemical 
composition and thermal stability of these for-
mulations. 
 
MATERIALS AND METHODS 
Cell culture and maintenance 
J774A.1 mouse Macrophage cell line was 
purchased from National Centre for Cell Sci-
ence (NCCS, Pune). All the cell culture prod-
ucts DMEM, FBS, Antibiotic and Antimy-
cotic solution were purchased from GibcoTM 
(Thermo Fisher Scientific). Culture flask and 
6-well plates were from Nunc (Thermo Scien-
tific). 
 
Reagents and solutions 
Starting material dry yeast (Saccharomy-
ces cerevisae) was purchased from a nearby 
authentic bakery (Polo Enterprises, Luck-
now). Sodium alginate low viscosity (a vis-
cosity of 2 % solution: 100-300 cP) was pur-
chased from Sigma Aldrich. Rhodamine B 
(Rd B) was purchased from sigma Aldrich. 
All other analytical chemicals and solvents 
used in the study were HPLC grade purchased 
from Merck (Mumbai, India). All aqueous so-
lutions were prepared from triple distilled wa-
ter (TDW). 
 
Preparation of β-glucan particles  
GP were prepared from baker’s yeast by 
slight modification of the alkaline and acidic 
extraction method described previously (Soto 
et al., 2010; Hunter et al., 2002), followed by 
either lyophilization or spray-drying. Briefly, 
the baker’s yeast was suspended in 200 ml of 
1M NaOH solution and stirred for 30 min at 
60 °C. The resulting material was heated to 
80 °C for 60 min and then centrifuged at 200 
x g for 10 min. The sediment was washed with 
TDW, pH adjusted to 4-5 with HCl and incu-
bated at 55 °C for 60 min. The alkali insoluble 
solids were then collected by centrifugation, 
washed first with TDW, and subsequently 4 
times with isopropanol and twice with 40 ml 
acetone. To overcome the problem of particle 
aggregation, the semisolid GP (after acetone 
washing) were sonicated (Sonics, UK) for 5 
min in TDW using an Ultrasonic Output fre-
quency of 20 Kilohertz per second at 192 
Watts and then homogenized (IKATM) at 
10,000 rpm for 10 min. The suspension was 
finally spray-dried using a Labultima Lu 20 
Spray Dryer (Labultima, Germany) with an 
inlet air temperature of 110-170 °C, an outlet 
air temperature of 90-120 °C and an atomizer 
pressure of 30-100 psi. Anthrone test was car-
ried out to confirm the carbohydrate nature of 
the off-white powder thus obtained.  
 
Rhodamine B labelling of GP and particle 
counting by flow cytometry 
A batch of GP was also labelled with rho-
damine B isothiocyanate. Briefly, the GP 
were incubated with rhodamine B isothiocya-
nate (dissolved in dimethyl sulfoxide), in so-
dium carbonate buffer (0.1 M, pH 9.2) over-
night at 37 °C in the dark; unreacted dye was 
quenched by incubation with Tris buffer 
(1.0 M, pH 8.3) for 30 min. The labeled GP 
were extensively washed with sterile water to 
remove color, dehydrated with absolute etha-
nol and acetone, and then dried in the dark at 
room temperature. The further processing 
(drug loading and alginate sealing) of these 
fluorescent particles was done in dark and 
flow cytometry analysis was performed for 
the counting of fluorescent dye (Rhodamine) 
tagged GP. 
 
Incorporation of Rifabutin (RB) into GP, a 
first-line anti-TB drug 
GP containing precipitated RB (GP-RB) 
were made as previously described (Soto et 
al., 2010), with a slight modification. Briefly, 
the dry GP were incubated in 0.2 N HCl with 
stock RB solution (100 mg RB per ml in 0.2 N 
HCl) for their hydration in a drug to polymer 
ratio of 1:1. To precipitate and trap RB inside 
the GP, Tris buffer (1M, pH 8) was added. 
The samples were then centrifuged twice, to 
remove the unprecipitated RB and buffer, fro-
zen at -80 °C and lyophilized. The resulting 
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‘GP-RB’ formulation had a strong violet-red 
colored appearance. 
 
Alginate sealing of RB-incorporated GP 
After loading the glucan particles with 
RB, the GP pores were sealed with calcium 
alginate hydrogel. 200 mg of GP-RB samples 
were incubated with 0.25 % sodium alginate 
(pH 8) at room temperature for 60 min and 
then centrifuged at 10,000 rpm for 5 min. The 
sealing process was repeated twice, and cal-
cium chloride (2 %, 5µL per mg GP) was 
added thereafter to allow overnight cross-
linking at room temperature. The resultant 
‘GP-RB-Alg particles’ were collected by cen-
trifugation and lyophilized to obtain an easily 
dispersible brick red colored powder that was 
stored at -20 °C.  
 
Particle size and zeta potential  
measurement of GP 
Particle size was determined by using a 
device (Mastersizer 2000, Malvern Instrue-
ments, UK) as described previously (Sharma 
et al., 2001), to determine if these are in the 
appropriate size range of 1-10 μm, for being 
phagocytosed by M. Briefly, about 5 mg of 
particles were dry-mixed with an equivalent 
amount of sodium lauryl sulfate (SLS) and 
suspended in one ml Milli-Q water by vortex 
mixing. This slurry was added into the sam-
pling beaker of the instrument until a laser ob-
scuration factor of > 10 % was achieved. The 
average size (n = 3) in µm was determined for 
all formulations. The zeta potential is a meas-
urement of the electric charge on the surface 
of the GP and indicates their physical stabil-
ity. The zeta potential of aqueous suspensions 
of spray dried GP and alginate coated GP 
were recorded using a Malvern Zetasizer 
(Nano-ZS 90, Malvern Instrument, UK). 
These measurements were taken at least three 
times with independent particle batches.  
 
Morphological characterization of GP 
The surface morphology, shape and size 
of the blank and drug loaded GP were visual-
ized by a Scanning Electron Microscope (Hi-
tachi S3700 N) at an accelerated voltage of 15 
kV. In addition, the Transmission Electron 
Microscope (JEOL, Japan JEM 2100) images 
of blank GP, drug loaded (GP-RB) particles 
and drug loaded-alginate sealed (GP-RB-Alg) 
particles were taken at the Indian Institute of 
Toxicology Research (IITR), Lucknow to 
study further morphological details of these 
particles.  
 
Thermogravimetric/Differential Thermo-
gravimetric analysis (TG-DTA) 
Thermal properties of the samples were 
studied by employing Thermogravimetric an-
alyzer (TGA) and differential Thermogravi-
metric analysis (DTA). TGA thermograms of 
sodium alginate, GP particles, alginate sealed 
GP-RB and pure RB were recorded by em-
ploying a TGA (Model TGA-50, Perkin 
Elmer) in the temperature range of 50–
750 °C, at a heating rate of 10° C/min in a ni-
trogen atmosphere. 
 
Validation of β-glucan by structural analy-
sis 
Fourier Transform Infra-red (FTIR)  
spectroscopy 
FTIR spectroscopy was applied to analyze 
the spray dried, lyophilized GP isolated from 
the yeast cell wall by alkaline and acidic ex-
traction method as described above. Infrared 
spectra of the GP were recorded with an FTIR 
spectrometer (Perkin Elmer Spectrum Ver-
sion 10.03.06) in the range of 4000~450 cm-1 
using KBr disk method.  
 
Solid-State Nuclear Magnetic Resonance 
(NMR) analysis 
The insolubility of particulate β-glucans 
posed a challenge during NMR analysis, due 
to the inability to detect undissolved sub-
stances. Thus a high resolution 13C-NMR of 
GP was performed in solid state to elucidate 
the glucan conformation. 
For ss-NMR analysis, the GP powder was 
filled into 3.2 mm Zirconium rotor. All 
ssNMR spectra were recorded on 600 MHz 
NMR spectrometer (Advance III, BrukerBio-
spin, Switzerland) operating at 600.154 MHz 
for 1H, and 150.154 MHz for 13C frequencies 
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with Bruker 3.2 mm DVT probe. Magic An-
gle Spinning (MAS) frequency was 10.0 kHz 
for all experiments. The spinning speed was 
controlled by Bruker MAS pneumatic unit 
within the accuracy of  2Hz. Recycle delay 
used for all experiments was 5 s. Total acqui-
sition time for each cross polarization (CP) 
experiments was 0.017 sec. All 13C CP-MAS 
NMR spectra were obtained with a spectral 
width of 315 ppm, 1K data points and 10 k 
scans with a contact time of 1.0 ms (milli sec-
ond). 
 
RB analysis in GP by HPLC 
RB analysis in GP was done by slight 
modification of an analytical method reported 
by Muttil et al. (2007). A Shimadzu (Japan) 
Class VP HPLC system with a Luna C18 col-
umn (5 m, 4.6 mm × 250 mm, Phenomenex, 
Torrance, USA) was used for the analysis. 
The mobile phase was a mixture of acetoni-
trile and phosphate buffer in a ratio of 45:55, 
which was filtered through 0.22 µm filter and 
degassed by sonication. RB was eluted at 7.2 
min at a flow rate of 1 ml/min and was moni-
tored using a UV detector set at 275 nm. 
The drug loaded-alginate sealed GP (GP-
RB-Alg) suspensions were weighed, ex-
tracted with 0.01 N HCl and then diluted in 
mobile phase after filtration through a 0.22 
µm filter. Correspondingly, standard curves 
were generated in the concentration range of 
5 – 40 µg RB /ml mobile phase (Figure 5B). 
The drug loading (LE) and encapsulation 
efficiency (EE) for RB within GP were calcu-
lated as follows: 
 % EE = (Experimental drug content /  
Theoretical drug content) x 100 (1) 
 
 % LE= (Amount of drug in microparticles / 
Amount of microparticles) x 100 (2) 
 
In vitro drug release and kinetics 
In vitro release of RB from spray dried GP 
was studied by using a USP Type II tablet dis-
solution test apparatus (Labindia, DISSO 
2000) at a stirring speed of 100 rpm and a 
temperature of 37 ± 0.5° C. A dialysis mem-
brane (Sigma-Aldrich) was cut into pieces 
and pre-treated as per the manufacturer in-
structions. Accurately weighed RB contain-
ing GP were filled in hermitically sealed dial-
ysis bags and immersed in two kinds of re-
lease media, phosphate-buffer (pH 7.4), and 
acetate buffer (pH 5.2) to simulate the cyto-
solic pH and late phagosomal pH, respec-
tively. The release media was supplemented 
with 1 % v/v tween 80 to prevent precipitation 
of released drug. Aliquots were withdrawn in 
duplicates at predetermined time intervals and 
fresh dissolution media were added at each 
time point to maintain the sink conditions. All 
the samples were filtered through a Millipore 
0.22 µm disposable filter, and filtrate was 
stored at −20 °C. The drug release was meas-
ured by reverse phase HPLC method as de-
scribed above.  
The intensity of absorbance was utilized 
to calculate the concentrations of the drug. 
Release profile was obtained by correlating 
time (h) versus drug release concentration (µg 
mL-1). The RB release data were used to study 
the mechanism of drug release. In attempts to 
study the drug release mechanism from the 
GP, the in vitro release data were fitted to var-
ious mathematical models (Zero-order, First-
order, Higuchi´s model and Korsmeyer-Pep-
pas model) to predict the drug release mecha-
nism and kinetics. Equations and other pa-
rameters of the mathematical models are 
shown in Table 1. Data were fitted and the lin-
ear regression of the mathematical models 
was evaluated using R2 (squared correlation 
coefficient). 
 
Cell culture and maintenance 
Mouse macrophage cell line (J774A.1) 
was procured from the National Centre of 
Cell Sciences (NCCS), Pune, India. The cells 
were grown and maintained in Dulbecco's 
Modified Eagle's medium (DMEM) supple-
mented with 10 % FBS and 1 % antibiotic an-
timycotic solution, in a controlled humidified 
atmosphere of 5 % CO2 and 37 °C.  
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In vitro uptake study 
Adherent 0.1 × 106 J774A.1 cells per well 
were seeded in a 96 well plate and incubated 
overnight at 37 °C in 5 % CO2. The cells were 
then exposed to fluorescent particles by re-
placing culture media in wells with Rhoda-
mine-tagged GP (10 Rd-GP per cell) sus-
pended in HBSS. After 5 min exposure, the 
cells were washed twice with PBS and visual-
ized under a fluorescent microscope (Nikon 
eclipse TiS) with a red filter for the presence 
of fluorescent particles.  
 
In vitro cell viability assay 
The cell viability of the RB-loaded glucan 
GPs was determined by measuring the inhibi-
tion of cell growth using a tetrazolium dye (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide [MTT]) assay. J774A.1 cells 
were seeded in 96-well plate at 1×106 
cells/well. Next, the cells were incubated with 
increasing concentrations (0–100 μg/mL) of 
the RB-loaded GP for 24 h in CO2 incubator 
at 37 °C. Then, 10 μL MTT solution (5.0 
mg/mL) was added to each well. The plates 
were incubated with MTT for an additional 4 
h at 37 °C. After that supernatant was re-
moved, 100 μL DMSO was added to fully dis-
solve the crystals. Absorbance at 490 nm, 
which is related to the number of metaboli-
cally active cells, was measured using a mi-
croplate reader (EXL-800; BioTek Instru-
ments). The cell viability was calculated us-
ing the following formula:  
Cell viability (%) =  
(Abs. sample / Abs. control) × 100.  
The viability of untreated controls was nor-
malized to 100 %. % Cytotoxicity = 100 − % 
cell viability. 
 
Data analysis 
All data were expressed as the mean ± 
standard deviation of the mean from three 
separate experiments. Statistical analyses 
were conducted using Origin 6.0 and Instat 
software. Results of the in vitro drug release 
study and cytotoxicity analysis were sub-
jected to analysis of variance (ANOVA). P 
values less than 0.05 were considered signifi-
cant. 
 
RESULTS 
GP formulation 
The initial batches of GP were prepared 
by alkaline and acidic extraction, followed by 
either homogenization or lyophilization. 
These particles showed conspicuous aggrega-
tion and fast sedimentation in aqueous sus-
pension (data not shown). However, in the 
later spray dried batch (GP2), the particle ag-
gregation was overcome by disrupting the 
particle aggregates prior to their complete 
drying and solidification, as described in the 
methods section and reported earlier by 
Hunter et al., (2002). The spray dried and ho-
mogenized particles were observed to remain 
in aqueous suspension for longer time periods 
(up to 1 h) as compared to the batches pre-
pared without spray drying (data not shown).  
 
Size and surface charge characteristics 
The characteristics of two representative 
batches of blank and drug loaded yeast-de-
rived GP formulations such as GP1- prepared 
by alkaline and acidic extraction method fol-
lowed by lyophilization, and GP2- prepared 
by sonication and spray drying method. The 
laser scattering studies (Figure 1B) revealed a 
much lower size range of spray dried parti-
cles, with more than 75 % particles in the size 
range of 1-4 µm, as compared to approxi-
mately 32 % particles in the batch prepared 
without spray drying (Figure 1A).  
To detect the presence of alginate layer 
over the formulated GP, we compared the zeta 
potential of the blank GP shells (Figure 1C) 
with that of the alginate sealed particles (Fig-
ure 1D). The alginate coating of GP reduced 
the apparent zeta potential (from -9.46 to -
20.7), indicating an increase in the negative 
surface charge. The shift in zeta potential of 
the particles is indicative of the presence of 
negatively charged alginate layer on the GP 
surface.  
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Particle morphology 
The SEM microphotographs showed the 
spray dried blank GP to be uniform, non-ag-
gregated and nearly spherical to ellipsoidal 
(Figure 2A). The images also revealed the 
size of blank particles to be 2-4 µm, which 
was in good correlation with the size distribu-
tion data obtained by laser scattering, indicat-
ing that the GP were fairly dispersed. The in-
corporation of RB and alginate coating of 
these particles was seen to be accompanied 
with a change in particle shape. SEM revealed 
that while blank particles were nearly spheri-
cal, the drug loaded GP were more hetero-
genous, somewhat angular and ellipsoidal 
(Figure 2B). Some small GP appeared to ag-
gregate with other particles after drug loading 
and alginate sealing.  
The TEM images of GP at all stages 
(blank GP, RB loaded GP and alginate sealed 
GP) show a highly porous structure (Figure 
3). The electron micrograph shows clear, 
small, on an average ~25 nm pores in the 
blank GP (Figure 3A). In contrast, the images 
of drug loaded GP show a rough and speckled 
surface containing prominent drug ‘nanopre-
cipitates’ or ‘nanocrystals’ on the surface as 
well as filling the pore space (Figure 3B) , as 
previously suggested by Soto et al., (2010). 
The smooth textured, glistening surface in the 
micrograph of Figure 3C is indicative of the 
presence of an alginate layer coating on the 
GP surface. 
 
 
 
Figure 1: Size and surface characterization of GP. The log-normal, volume-average particle size distri-
bution of typical batches of (A) lyophilized and (B) spray dried GP, as assessed by laser scattering. The 
zeta potential of (C) blank GP, and (D) RB-loaded, alginate sealed GP. 
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Figure 2: Scanning Electron Micrographs of (A) blank GP and (B) RB-loaded, alginate sealed GP 
 
 
 
Figure 3: Transmission electron micrographs of (A) blank GP, (B) RB loaded unsealed GP, and (C) 
RB-loaded, alginate-sealed GP at 30,000 magnification. The red bar at bottom of images represents a 
50 nm scale. The images reveal the porous nature of particles. Arrows in panel B point towards RB 
‘nanoprecipitates’ or ‘nanocrystals’ formed within the GP pores in unsealed GP. The smooth and glis-
tening surface visualized in Panel C, indicates the presence of an alginate layer sealing the drug loaded 
GP. 
 
 
Structural studies of glucan in particles 
Fourier Transform Infra-red (FTIR) analysis 
The prepared formulation was validated 
as particulate β-glucan by the FTIR analysis. 
The recorded FTIR spectra of blank GP for-
mulation (Figure 4A), showed the typical sig-
nal pattern characteristic for β-1,3-D-glucan 
isolated from yeast (Hromadkova et al., 2003; 
Zechner-Krpan et al., 2010). The IR bands in 
the region of 928–1200 cm–1 (mainly due to 
C-C and C=O stretching vibrations in pyra-
noid rings) indicate the presence of polysac-
charides as major component(s). Absorption 
peaks at 3390.55 cm–1 indicate O-H stretch, as 
the free hydroxyl groups absorb in the region 
of 3650–3500 cm–1., while the signals at 2401 
and 1215.72 cm–1 indicate C-H stretch and 
CH2OH stretch respectively. The strong ab-
sorption peak at 890.24 cm-1 is characteristic 
of β-glycosidic bonds, i.e. (C1–H) defor-
mation mode, and, therefore, indicates the 
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presence of β-glucans. Absorption at 760 cm–1 
implies the presence of α-glycosidic bond and 
could be explained by small concentrations of 
mannan, containing the above mentioned 
bond. The concentration of residual proteins 
in the β-glucan preparations with the presence 
of amide bands (amide I and amide II) vibra-
tions of proteins at 1628 and 1406 cm–1, and 
almost similar results published by Hromad-
kova et al. (2003). 
 
Solid state NMR spectroscopy 
The high resolution 13C NMR spectra of 
the GP was recorded and compared with that 
of the reported spectra of native β-1,3-D-glu-
can in order to gain an insight into their pri-
mary and secondary structures in relation to 
their gel forming, physical and immunomod-
ulatory properties (Falch et al., 2000). 
Primary structure 
The 13C NMR spectrum of particulate glu-
can in solid state (Figure 4B) was seen to be 
similar to that of native glucan reported else-
where (Du et al., 2012; Saito et al., 1987). The 
chemical shifts from GP were observed at 
105.62, 87.19, 78.74, 76.47, 70.17, and 63.07 
ppm, which correspond to the C-1, C-3, C-5, 
C-2, C-4, and C-6 respectively. Thus, the 
NMR spectrum of the formulation verified the 
(1→3) β-D-glucan structure of GP. In addi-
tion, another small signal (C6*) was observed 
at 69.3 ppm, which is a characteristic peak 
due to β-1,6 branching (Du et al., 2012). The 
degree of branching (DB) of the water-insol-
uble yeast glucan is reported to be as low as 
0.003 (Kim et al., 2000). Thus the NMR spec-
trum of GP confirmed the β-1,3 glucans struc-
ture with 1,6-linked side chain(s). 
Since the C3 peak was found to resonate 
at 85.98 ppm (C-3b), a characteristic feature 
of the triple helix conformation (Saito et al., 
1987), the prepared GP are expected to ex-
hibit laminarin-type triple-helix confor-
mation. On the contrary, the C3 peak of lenti-
nan resonates at 89.6 ± 0.5 (C-3a) character-
istic of the presence of curdlan-type single-
helical form. Accordingly, the relative peak 
intensities between the C-3a and C3b peaks 
also suggest the presence of triple helix in GP.  
Thermal stability analysis 
The thermogravimetric curves (Figure 
4C) were obtained for the GP-RB-Alg parti-
cles and their individual components, RB, 
blank GP and alginate. These curves show the 
variation of mass (%) as a function of temper-
ature (° C). The TGA curve of sodium algi-
nate suggests lower thermal stability than of 
glucan.  
Both sodium alginate and glucan showed 
similar type of weight loss pattern before de-
composition. The decomposition temperature 
of sodium alginate and GP was lower than 
that of cross linked, drug loaded GP. How-
ever, RB thermogram shows sharp decompo-
sition after melting and almost complete 
weight loss at ~ 650 °C. The TGA thermo-
grams of the alginate sealed, RB loaded parti-
cles showed a decomposition and weight loss 
pattern similar to that of RB. However, it 
showed higher thermal stability than the blank 
GP and sodium alginate.  
The RB thermograms showed an endo-
thermic peak at around 192 °C due to melting. 
There was no characteristic peak of RB in the 
thermogram of RB loaded GP-RB-Alg. These 
results indicated that RB was fairly dispersed 
in the GP.  
 
Drug loading and encapsulation efficiency 
of the formulation 
HPLC chromatograms demonstrating RB 
peaks in standard and sample GP are illus-
trated in Figure 5A and 5C, respectively. 
Standard calibration curves for RB analysis 
were linear in the concentration range of 5–40 
µg/ml and showed regression coefficient (r2) 
> 0.995 (Figure 5B). The RB analysis by 
HPLC showed an increase in drug entrapment 
efficiency of GP formulations from 54.97 % 
to 80.74 % upon spray drying. The drug: pol-
ymer ratio of 1:1 was more or less maintained 
as such, since the drug loading was obtained 
up to ~40.5 %, indicating that the spray dried 
GP contain on an average, 40.5 % drug (RB) 
and 59.5 % polymer(s), including β-glucan 
and alginate. 
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Particle enumeration by flow cytometry 
revealed an average number of 1.68×108 Rho-
damine-labelled, blank GP (Rd-GP) per mg 
dry weight of the formulation. Upon drug 
loading and sealing, the particle number de-
creased to an average of 11.8 x 106 particles 
per mg dry weight of the GP-RB-Alg formu-
lation. Accordingly, each GP was found to 
contain on average, 34.3 pg RB.  
 
In vitro release kinetics of loaded drug 
Upon internalization by Mϕ, the particles 
may be delivered either to classical, acidified 
phagosomes that undergo fusion with lyso-
somes; or may co-localize with bacteria in 
maturation-arrested phagosomes. The in vitro 
drug release from the GP-RB-Alg was thus 
studied at both cytosolic and lysosomal pH as 
shown in Figure 6.  
The overall release behavior of RB from 
the alginate sealed GP was seen as biphasic 
with an initial burst effect, followed by a sub-
sequent slow release as depicted in Figure 6A. 
The first 10 min of drug release data showed 
10.29 % of RB release at pH 7.4, and 34.26 % 
release at pH 5.2. The release pattern was 
nearly linear up to 4 h showing 66.86 % re-
lease at pH 7.4. During the same period, the 
release at pH 5.2 was 73.26 %. The curves 
tended to flatten out beyond this.  
 
 
 
Figure 4: Structural and Thermal Stability analyses of GP. (A) FTIR spectrum of (spray dried) GP show-
ing that particles were β-1,3 linked glucan. (B) Solid-State 13C-NMR Spectra of (spray dried) GP showing 
that the particulate glucan possesses a triple helical conformation. (C) Thermogravimetric curves of 
blank GP, Alginate, RB and RB loaded alginate sealed GP. Heating was done at a rate of 10 °C min-1 
from 50 °C to 750 °C. 
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Figure 5: Quantitative analysis of RB. (A) HPLC chromatogram of RB in PBS buffer, (B) Standard curve 
of pure RB and (C) chromatogram of RB released from alginate sealed, RB-loaded GP sample. 
 
 
The data indicated faster drug release at 
pH 5.2 than at 7.4 from the GP formulation 
(p < 0.05) up to 48 h. However, by 3 days, the 
cumulative amounts of RB release appeared 
to be almost same in both samples (p > 0.05), 
thereby indicating the possibility of a lack of 
pH-dependence over a longer time period.  
Various models of drug release were em-
ployed to analyse the drug release from parti-
cles (Table 1). The initial drug release up to 4 
h seemed to be concentration dependent (first 
order kinetics), showing correlation coeffi-
cient (R2) value(s) of 0.953 at pH 7.4 and 
0.891 at pH 5.2. The release pattern, however, 
showed best fit to the Higuchi model indicat-
ing a diffusion controlled drug release from 
the GP. 
 
In vitro cellular uptake and cytotoxicity of 
GP-RB-Alg  
Microscopic examination of Mϕ exposed 
to the Rd-labeled GP-RB-Alg, revealed the 
presence of internalized particles emanating 
bright red fluorescence (Figure 7). The bright 
field images of Rd-labeled GP-exposed cells 
showed conspicuous granulation within the 
cytoplasm in comparison to the unexposed 
control cells, indicating uptake of fluores-
cently labeled GP by Mϕ within 5 min of ex-
posure. To verify that experimental doses of 
Rifabutin loaded alginate sealed GP are not 
cytotoxic upon uptake by macrophages, we 
performed MTT viability assay against 
J774A.1. The RB loaded GP did not show cy-
totoxicity to J774 cells, upon 24 h exposure 
up to a concentration of 80 μg/ml (Figure 8). 
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However, even upon of RB loaded GP expo-
sure at 100 µg/mL concentrations the cells 
were about 90 % viable, suggesting these par-
ticles to be fairly biocompatible with the mu-
rine Mϕ cell line. 
 
DISCUSSION 
The smaller particle dimensions and 
higher uniformity (narrow size distribution) 
of the spray dried blank GP than the lyophi-
lized particles, was in agreement with prior 
reports (Hunter et al., 2002; Zechner-Krpan et 
al., 2010). Homogeneous, small particles in 
the range of 0.3 to 10 µm are known to be 
readily phagocytosed by Mϕ and signal cellu-
lar activation.  
RB has been recommended by the WHO 
as a first-line agent for treatment of MDR-TB 
and is accepted as an effective replacement 
for Rif (Sirgel et al., 2013). Since the Rif-re-
sistant/RB-susceptible isolates have been re-
ported in much large numbers, RB has been 
suggested for the treatment MDR-TB and 
XDR-TB for positive treatment outcome in 
these patients. In addition, RB shows fewer 
drug-drug interactions and better tolerance by 
patients developing Rif-related adverse ef-
fects (Horne et al., 2011). It is more lipid sol-
uble than Rif, resulting in more-extensive tis-
sue uptake and was therefore, chosen for en-
trapment within the GP. 
 
  
Figure 6: In vitro patterns of RB release from alginate sealed GP in cytosolic (phosphate buffer, pH 7.4) 
and phagolysosomal (acetate buffer, pH 5.2) conditions at 37 °C. (A) First 6 h analysis showed greater 
release of RB at pH 5.2 than at 7.4. (B) Overall RB release at cytosolic (pH 7.4) and phagolysosomal 
(pH 5.2) conditions up to 72 h 
 
Table 1: Squared correlation coefficient (R2) and coefficients obtained by mathematical model fitting to 
RB release data over 72 h 
Mathematical Model 
(equation) 
pH 7.4 pH 5.2 
R2 K n R2 k N 
Zero order [F=k0t] 0.5421 (k0) 0.8724 - 0.4722 0.7241 - 
First order [ln (1-F) = - kf t] 0.7951 (kf) 0.0269 - 0.7124 0.028 - 
Higuchi [F = kH t1/2] 0.9530 (kH) 0.3548 - 0.9737 0.5640 - 
Korsmeyer-Peppas [F=kmtn] 0.9057 (km) 0.3658 0.5558 0.9547 0.2435 0.2519 
‘F’ denotes fraction of drug released up to time t; ‘R2’ is squared correlation coefficient; k0, kf, kH and km are constants of the 
mathematical models; ‘n’ is the release exponent of the Korsmeyer-Peppas model. 
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Figure 7: In vitro phagocytic uptake of Rhodamine B-labeled alginate sealed GP (Rd-GP) by J774 cells. 
(A) Bright field and (B) fluorescent micrograph of Rd-GP exposed macrophage at 20X magnification. 
White arrows show the internalized Rd-YDGP within macrophage after 5 min exposure 
 
 
 
Figure 8: Effects of RB-GP on J774A.1 Macro-
phage cell viability. Cells were treated with various 
concentrations (0-100 μg/ml) of RB loaded GP for 
24 h, after which their viability was detected by 
MTT assay. Data expressed as mean ± S.D from 
three independents experiments (*p < 0.05, 
** < 0.01). 
 
The HPLC studies revealed that despite a 
lower initial drug: polymer (1:1) ratio, the 
spray dried particles (GP2) had much higher 
drug loading as compared to the lyophilized 
particles (GP1), where an initially higher 
drug: polymer (2:1) ratio was taken. Since the 
spray dried blank GP (GP2) exhibited consid-
erably improved characteristics such as small 
size, high uniformity, dispersion, yield, drug 
loading and drug encapsulation as compared 
to the lyophilized particles (GP1), the former 
were chosen for further experiments in this 
study. 
The spray dried blank GP loaded with 
50 % RB (1:1 drug: GP) showed an entrap-
ment of 34.3 pg RB per GP. These values 
were much higher than those achieved by 
Soto et al. (2010) who reported a drug content 
of 0.2 to 0.66 pg Rif per GP, prepared by load-
ing 10 % and 33 % w/w Rif per GP, respec-
tively (Soto et al., 2010). It is important to 
note that the Rifampicin-loaded GP reported 
earlier by Soto et al. (2010) were prepared by 
yeast cell wall extraction followed by lyophi-
lization and not spray drying. Sonication and 
spray drying leads to formation of micronized 
particles with increased porosity which leads 
to loading of large payload molecules within 
GP pores. The unexpectedly high drug load-
ing obtained in the spray dried particles may 
be explained in terms of the microstructure of 
the porous blank GP formed by spray drying. 
We therefore, studied the particle morphology 
of GP at various stages of preparation by elec-
tron microscopy. In agreement with the re-
ports by other investigators, the scanning 
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electron micrographs (Figure 2) revealed a 
homogeneous, non-aggregated characteristic 
‘ellipsoidal’geometry of the spray-dried par-
ticles with an irregular surface (Yu et al., 
2015). The β-glucan particle morphology and 
dimensions have earlier been shown to be in-
fluenced by the selection of drying method 
(Zechner-Krpan et al., 2010). Spray dried par-
ticulate glucan samples have been seen to pre-
serve the ellipsoidal shape of yeast cells, and 
had lower viscosity than those dried by sol-
vent exchange and lyophilization (Hromad-
kova et al., 2003). Additionally, the ‘ellipsoi-
dal’ glucan particle geometry has been shown 
to be advantageous for Mϕ uptake (Garcia-
Contreras et al., 2008). The Transmission 
Electron Micrographs (Figure 3) clearly re-
veals these particles to be highly porous, 
thereby permitting entrapment of drug mole-
cules as ‘nano-drug precipitates’ or ‘nano-
crystals’ of less than 50 nm within the GP 
(Soto et al., 2010). The presence of alginate 
layer on the GP surface was verified by the 
smooth, glistening porous surface visualized 
in the electron micrograph of sealed particles 
(Figure 3C) as well as by the negative changes 
in zeta potential (Figure 1C and D). 
Since the glucan shell is formed prior to 
drug loading, it forms the structural frame-
work of the GP-RB-Alg formulation. The 
spray dried particles are exposed to very high 
temperatures ranging from 90-170 °C (inlet 
and outlet air temperatures) and an atomizer 
pressure of 30-100 psi. The loading of appre-
ciably higher magnitudes of drug within spray 
dried GP may be attributed to the efficient 
drying of the polymeric glucan resulting in 
formation of a more porous microstructure of 
the GP, as compared to that by lyophilization. 
Consequently, during drug loading, the ‘drug-
nanoprecipitates’ get seated into the well-
formed porous microstructure of the GP. The 
incubation of drug-loaded GP with alginate 
has been hypothesized to form a hydrogel ma-
trix inside them, so as to physically entrap the 
payload drug, and seal the pores to retain the 
‘nanodrug precipitates’ seated within them. 
The use of calcium chloride to cross-link the 
alginate layer on GP surface is known to fur-
ther strengthen and stabilize the particles 
(Borges et al., 2006).  
The FT-IR analysis verified the primary 
β-1,3/1,6-glucan structure of spray dried par-
ticulate glucan, while the 13C NMR elucidated 
the triple helix conformation of β-glucan in 
these particles. This study is in agreement 
with a previous study which showed that the 
extraction procedure combined with spray-
drying allowed the retention of the native β-
glucan microstructure of the GP, with a triple-
helix conformation (Zechner-Krpan et al., 
2010). Another study by Hromadkova et al., 
(2003) reports the immunomodulatory activ-
ity of yeast-derived spray dried particulate 
glucan to be almost double of that with the 
particle samples dried by either solvent ex-
traction or lyophilization (Hromadkova et al., 
2003).  
The thermal characterization data indi-
cated high thermal stability of the GP formu-
lation. The GP-RB-Alg formulation was 
~95 % stable at 170 °C temperature of the in-
let air during spray drying. The polymer gel 
strength of alginate beads has been reported 
to depend on the concentration of calcium 
chloride used during preparation, the nature 
of the ionic salt used, sodium alginate concen-
tration, and the presence of other polymers 
(Bajpai et al., 2006). The high thermal stabil-
ity of alginate sealed GP might be attributed 
to the calcium alginate crosslinks, formed on 
the surface of particle shells, thereby probably 
lowering the elimination of small molecules 
like CO2, CO, or NaCl, and acting as an infu-
sible support during the decomposition of GP 
formulation. Similar observation was also re-
ported by Patil and Sawant (2009) during 
DSC analysis of carvedilol drug encapsulated 
within alginate microspheres. 
The initial burst release appears to come 
from the RB molecules adsorbed on the GP 
surface. The subsequent release was rather 
sustained and the loaded drug was released 
constantly and slowly up to ~24 h, whereafter 
it almost reached a plateau. The GP-RB-Alg 
formulations released ~90 % of their drug 
content at both the pH, over the first 72 h 
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when tested in vitro. Soto et al. (2010) demon-
strated a release of 70–95 % of the loaded 
drug by GP over 17 h in PBS. They also 
demonstrated that the alginate or chitosan 
sealing retards drug release from GP and 
thereby, prolong the delivery of therapeutic 
molecules.  
Although alginate is more soluble at pH 
7.4 than at pH 5.2, we observed a higher drug 
release at pH 5.2 than at pH 7.4 from GP-RB-
Alg formulation. The observation may be at-
tributed to the greater porosity and hydration 
of alginate matrix in acidic medium (Hodsdon 
et al., 1995) and a 16-fold higher RB solubil-
ity at pH 5.2 than at pH 7.4 (Marzolini et al., 
2001). These particles may be expected to 
control drug release inside classical or matu-
ration-arrested phagosomes over a few days 
to kill the replicating bacteria.  
Upon mathematical analysis, the data for 
in vitro drug release from GP-RB-Alg fitted 
the best to Higuchi’s model (Table 1). The 
drug release data was also fitted to 
Korsmeyer-Peppas equation, which is often 
used to describe the drug release behaviour 
from polymeric systems when the mechanism 
is not well-known or when more than one type 
of release phenomena is involved. In the 
Korsmeyer-Peppas model equation (Table 1), 
‘k’ is the rate constant, and ‘n’ is the release 
exponent providing information about the 
mechanism of drug release. At pH 5.2, the 
Korsmeyer-Peppas release exponent (n) value 
of < 0.45, indicated the drug release from the 
more porous and hydrated alginate matrix to 
be mediated by Fickian diffusion (Grassi and 
Grassi, 2005). On the other hand, at pH 7.4, 
the value of ‘n’ (between 0.45 and 0.89) indi-
cates an anomalous (non-fickian) transport 
mediated drug release from these particles 
(De Kee et al., 2005). It is suggested that at 
this pH, boundary conditions such as the pres-
ence of stagnant layer or a hydrogel on the re-
lease surface, results in an increased value of 
‘n’. The sharp front formed by penetration 
into gel matrix is assumed to slowly move 
into polymer linearly with time. The 
Korsmeyer-Peppas model has been reported 
to become identical with Higuchi model at 
nearly equal to 0.5 values of release exponent 
‘n’ (Carriazo et al., 2010; Karewicz et al., 
2010). This was observed in our studies show-
ing drug release at pH 7.4 (Table 1), where the 
release exponent (n) obtained was nearly 0.5 
and ‘k’ values obtained with the Higuchi and 
Korsmeyer-Peppas models were quite simi-
lar.  
Thus, the mechanism of drug release from 
GP appears to be as follows: Alginate matri-
ces undergo hydration to create a gel layer, 
water penetrates the thin alginate layer sealing 
the GP, entering into polymeric matrix 
through small pores and channels; slowly dis-
solving and depleting the drug, which is re-
leased by diffusion from the pores into sur-
rounding release medium. Leaching out of the 
drug from the pores and internal domains is 
expected to create empty spaces, permitting 
progressive hydration of the porous interior of 
alginate matrix. 
The immunological activity of β-glucan is 
known to depend on particle dimensions and 
thus can be improved by reducing the GP size. 
The small size of particles, the triple helix 
configuration and a low degree of branching 
of the β-1,3-linked glucan polymer appears to 
advocate in favour of an effective im-
munostimulatory and therapeutic potential of 
this formulation.  
The in vitro uptake studies suggested that 
the GP were rapidly internalized by the mouse 
Mϕ cell line within 5 min of exposure. Our 
earlier, preliminary studies showed that GP 
uptake by the Mϕ started in less than 2 min of 
exposure. The 5 min exposure time was cho-
sen to ensure sufficient and reproducible up-
take. The GP were seen to retain their pay-
loads for sufficient time to allow phagocytic 
uptake by Mϕ.  
Since each GP-RB-Alg has numerous 
‘drug nanoprecipitates’ (as seen in the trans-
mission electron micrographs), the uptake of 
even a single GP by macrophage would result 
in the intracellular delivery of a large number 
of drug nanoparticles. We therefore, expect 
the phagocytic uptake of GP-RB-Alg parti-
cles to result in high intracellular drug con-
centrations, as demonstrated in our previous 
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studies with PLA based microparticles 
(Sharma et al., 2001). 
Spray dried particles have been shown to 
be more effective at enhancing phagocytosis 
by peritoneal Mϕ than those prepared without 
spray drying (Hunter et al., 2002). GP are well 
known to bind dectin-1 receptors on Mϕ and 
DC (Batbayar et al., 2012), and are, therefore, 
capable of targeting and activating the innate 
immune system. Receptor-mediated endocy-
tosis offers the potential to target selected cell 
types and enhance uptake of particulate mate-
rial. Since GP are specifically recognized by 
Mϕ cells that express glucan receptors, they 
find potential application as Mϕ targeting for-
mulations. This targeted delivery system has 
been recently shown to deliver loaded pro-
teins efficiently and specifically to Mϕ with-
out affecting non-phagocytic cells, such as 
NIH3T3, AD293, HeLa, and Caco-2 (Yu et 
al., 2015). This study therefore strongly advo-
cates that GP can act as Mϕ targeting carriers 
to deliver the loaded drug molecules within 
these phagocytic cells known to harbor TB 
bacilli.  
The immune responses and anti-mycobac-
terial efficacy of these RB loaded GP formu-
lations are yet to be determined. Nevertheless, 
it is encouraging to note that the GP-mediated 
Rif delivery to Mϕ, even at sub-MIC concen-
trations has been shown to enhance the anti-
microbial effects of Rif (Soto et al., 2010). In 
line with this, the fact that our particles con-
tain a high payload (~41 %) of RB, which re-
portedly has a much higher efficacy (8 times 
lower MIC range) than Rif, advocates for a 
much higher anti-mycobacterial potential of 
these particles, than that of previously re-
ported GP containing only 10 % Rif. A slow-
release drug delivery system also promises to 
reduce the frequency (days) and amount of 
drugs (doses) needed during conventional 
treatment. In this context, the in vitro release 
data from the GP-RB-Alg offers hope for the 
controlled release of the loaded antibiotics 
over a few days within the Mycobacteria in-
fected Mϕ. Such drug containing GP, there-
fore, appear to be advantageous for TB chem-
otherapy, since they offer hope for improving 
patient compliance, targeting Mϕ-resident 
Mycobacteria, and perhaps also modulating 
the host’s immunity towards a favorable ther-
apeutic outcome.  
 
CONCLUSION 
This study clearly revealed that the glucan 
particles prepared by alkaline and acidic ex-
traction followed by spray drying technology, 
exhibited considerably improved characteris-
tics such as small size, uniformity, non-ag-
glomeration tendency, high yield recovery 
and high magnitude of drug loading, as com-
pared to those prepared without spray drying. 
Characterization of these particles showed a 
triple-helical conformation of β-1,3/1,6-
linked glucans with a high thermal stability. 
The spray drying technology permitted a 
higher drug loading than those prepared with-
out spray drying, leading to achievement of 
magnitudes of (about 60 times) higher drug 
loading that reported by Soto et al., (2010). 
This is significant because low drug loading 
on the other hand, implies a need for repeated 
administration and inability to address the 
non-compliance problem and thus a risk for 
development of drug resistance. The drug re-
lease from alginate sealed GP was observed 
to be sustained and obeyed Higuchi’s kinet-
ics. The TEM images clearly reveal the pres-
ence of drug ‘nanoprecipitates’ or 'nanocrys-
tals’ filling the cavities of the GP. Thus, the 
phagocytic uptake of even a single GP by 
macrophage would result in the targeted intra-
cellular delivery of a large number of drug na-
noparticles. Thus, the spray dried GP-based-
formulation technology holds promise for 
high drug loading and sustained release for 
sufficiently longer time periods, and thus has 
potential application as alternative dosage ve-
hicles to target and deliver a large payload of 
anti-TB drug(s) to macrophage resident My-
cobacteria. Our future studies are directed to-
wards determining the immuno-stimulatory 
and antimicrobial potential of these GP for-
mulations. 
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